Morgan Stanley
ENTX icon

Morgan Stanley’s Entera Bio ENTX Stock Holding History

Morgan Stanley’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444 Buy
+400
New +$561 ﹤0.01% 7632
2024
Q1 		– Sell
-2,000
Closed -$1.2K – 7865
2023
Q4 		$1.2K Buy
2,000
+1,000
+100% +$682 ﹤0.01% 7186
2023
Q3 		$725 Sell
1,000
-100
-9% -$74 ﹤0.01% 7271
2023
Q2 		$928 Buy
1,100
+100
+10% +$85 ﹤0.01% 7306
2023
Q1 		$1.16K Hold
1,000
– – ﹤0.01% 7330
2022
Q4 		$730 Sell
1,000
-35,166
-97% -$25.5K ﹤0.01% 7518
2022
Q3 		$38K Buy
36,166
+33,400
+1,208% +$50.4K ﹤0.01% 6529
2022
Q2 		$4K Sell
2,766
-2,190
-44% -$4.87K ﹤0.01% 7444
2022
Q1 		$14K Sell
4,956
-1,012
-17% -$2.43K ﹤0.01% 7280
2021
Q4 		$17K Buy
5,968
+590
+11% +$2.21K ﹤0.01% 7274
2021
Q3 		$25K Buy
5,378
+3,188
+146% +$16.3K ﹤0.01% 7011
2021
Q2 		$13K Buy
+2,190
New +$8.1K ﹤0.01% 7151

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

Morgan Stanley's ENTX Position: Q1 2026 in Review

Morgan Stanley opened a new position in Entera Bio (ENTX) in Q1 2026: 400 shares worth $444. The stake represents ﹤0.01% of the portfolio and ranks #7632 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in ENTX as recently as Q4 2023.

Morgan Stanley first reported a position in ENTX in Q2 2021 and has held it in 12 quarters since. The position peaked at $38K in Q3 2022. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Morgan Stanley held 400 shares of Entera Bio worth $444 as of Q1 2026.
  • Entera Bio was a new Morgan Stanley position in Q1 2026.
  • Entera Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7632 holding.
  • Morgan Stanley first reported a position in Entera Bio in Q2 2021 and has held it in 12 quarters since.
  • Morgan Stanley's Entera Bio position peaked at $38K in Q3 2022.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.